Metastatic Triple Negative Breast Cancer Clinical Trials 2023
Browse 97 Metastatic Triple Negative Breast Cancer Medical Studies Across 330 Cities
6 Phase 3 Trial · 1076 Metastatic Triple Negative Breast Cancer Clinics
NUV-868for Pancreatic Cancer
SGN-B7H4Vfor Endometrial Cancer
Triple Negative Breast Cancer (for Tumors > 5 Cm)for Breast Cancer
BMS-986340for Gastric Cancer
TAK-676for Oral Squamous Cell Carcinoma
BT8009for Ovarian Neoplasms
Alpelisibfor Breast Cancer
Pembrolizumabfor Breast Cancer
Pembrolizumabfor Breast Cancer
SGN-PDL1Vfor Esophageal Cancer
What Are Metastatic Triple Negative Breast Cancer Clinical Trials?
Metastatic triple-negative breast cancer is a branch of breast cancer that is known for its aggressive nature. As derived from the name of this condition, this breast cancer is largely metastatic, which means that it often spreads to other parts of the body.
The incidence of metastatic triple-negative breast cancer is around 15% of all diagnosed breast cancer cases, with many patients experiencing relapse or recurrence after first-line treatment. The resilience of the cancer is largely due to its treatment resistance. Additionally, its metastatic tendencies make the condition more difficult to cure.
Once this breast cancer has metastasized, patients' prognoses worsen. Patients diagnosed with metastatic triple-negative breast cancer also have a higher fatality rate than those who have other forms of cancer. Therefore, it's important to implement clinical trials to find more effective treatment methods.
Why Is Metastatic Triple Negative Breast Cancer Being Studied Through Clinical Trials?
Due to ineffective first-line treatments for metastatic triple-negative breast cancer, the condition is considered incurable. Patients who undergo standard cancer-related treatments are also more likely to experience recurrence or relapse. Considering the gap in effective medical treatment, it can be deduced that this type of breast cancer requires more efficient and thorough research.
As clinical trials are undertaken to expand the clinical catalog for metastatic triple-negative breast cancer, professionals within the medical field are better able to work toward improved treatment methods. Similarly, it allows for better survival rates, and once treatments prove effective, researchers can also study potential curative therapies.
What Are The Types of Treatments Available For Metastatic Triple Negative Breast Cancer?
Metastatic triple-negative breast cancer is typically treated with generic first-line cancer treatments. These treatments include radiation and chemotherapy. Patients may also be eligible for surgical intervention in cases with no metastasis.
Some patients may be prescribed both chemotherapy and surgery. Chemotherapy may help to shrink localized tumors before excising them. Still, it can also be used as a second-line treatment post-surgery. As a secondary treatment, chemotherapy is used as a preventative measure to reduce the risk of further metastasis and recurrence.
Currently, medical treatments such as immunotherapy and drug-based management are being researched for their efficacy via clinical trials.
What Are Some Recent Breakthrough Clinical Trials For Metastatic Triple Negative Breast Cancer?
Like most cancers, metastatic triple-negative breast cancer is continuously being studied through clinical trials. Over time, these trials have tested various treatments and their efficacy, with some producing ground-breaking results that may pave the way for more effective treatments.
2021: Sacituzumab Govitecan VS Chemotherapy – In a clinical trial testing the efficacy of Sacituzumab Govitecan against an industry-standard treatment (chemotherapy). According to the trial results, participants who were given the antibody-drug had better survival rates with lower recurrence instances.
2023: Pembrolizumab Treatment for Metastatic TNBC – In one of the most recent trials, researchers studied participants who were given chemotherapy treatment in conjunction with a drug-based treatment (Pembrolizumab). Results showed that patients who participated in the trial had an increased chance of survival post-treatment.